Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
<p>Gene expression of major signalling pathways and multiplex immunohistochemical comparison of markers between timepoints and tumor sites. A) Gene expression of related oncogenic signalling pathways between treatment timepoints and site, B) Estimated mean difference of proteins and pathways b...
Збережено в:
| Автор: | James S. Wilmott (15008931) (author) |
|---|---|
| Інші автори: | Hussein Tawbi (15054769) (author), Johnathan A. Engh (15054772) (author), Nduka M. Amankulor (15054775) (author), Brindha Shivalingam (15054778) (author), Hiya Banerjee (15054781) (author), Ismael A. Vergara (15054784) (author), Hansol Lee (15054787) (author), Peter A. Johansson (15054790) (author), Peter M. Ferguson (15054793) (author), Philippe Saiag (15054796) (author), Caroline Robert (15032672) (author), Jean-Jacques Grob (15054799) (author), Lisa H. Butterfield (15035537) (author), Richard A. Scolyer (10778711) (author), John M. Kirkwood (15023483) (author), Georgina V. Long (11420813) (author), Michael A. Davies (14932995) (author) |
| Опубліковано: |
2025
|
| Предмети: | |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Схожі ресурси
Схожі ресурси
-
Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
за авторством: James S. Wilmott (15008931)
Опубліковано: (2025) -
Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
за авторством: Qingsheng Xu (17078830)
Опубліковано: (2025) -
Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
за авторством: Qingsheng Xu (17078830)
Опубліковано: (2025) -
Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
за авторством: Tom Wei-Wu Chen (15053003)
Опубліковано: (2025) -
Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
за авторством: Tom Wei-Wu Chen (15053003)
Опубліковано: (2025)